These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33858364)

  • 1. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases.
    Sakai N; Furukawa K; Takayashiki T; Kuboki S; Takano S; Ohtsuka M
    BMC Cancer; 2021 Apr; 21(1):412. PubMed ID: 33858364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
    Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
    J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.
    Margonis GA; Buettner S; Andreatos N; Sasaki K; Ijzermans JNM; van Vugt JLA; Pawlik TM; Choti MA; Cameron JL; He J; Wolfgang CL; Weiss MJ
    Ann Surg; 2017 Oct; 266(4):641-649. PubMed ID: 28657938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients.
    Gholami S; Kemeny NE; Boucher TM; Gönen M; Cercek A; Kingham TP; Balachandran V; Allen P; DeMatteo R; Drebin J; Jarnagin W; D'Angelica M
    Ann Surg; 2020 Aug; 272(2):352-356. PubMed ID: 32675549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
    Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
    Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases.
    Goffredo P; Utria AF; Beck AC; Chun YS; Howe JR; Weigel RJ; Vauthey JN; Hassan I
    J Gastrointest Surg; 2019 Oct; 23(10):1957-1963. PubMed ID: 30276588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors differ according to KRAS mutational status: A classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis.
    Moro A; Mehta R; Tsilimigras DI; Sahara K; Paredes AZ; Bagante F; Guglielmi A; Alexandrescu S; Poultsides GA; Sasaki K; Aucejo FN; Pawlik TM
    Surgery; 2020 Sep; 168(3):497-503. PubMed ID: 32675031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
    Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS
    BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.
    Gagnière J; Dupré A; Gholami SS; Pezet D; Boerner T; Gönen M; Kingham TP; Allen PJ; Balachandran VP; De Matteo RP; Drebin JA; Yaeger R; Kemeny NE; Jarnagin WR; D'Angelica MI
    Ann Surg; 2020 Jan; 271(1):147-154. PubMed ID: 29995686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Buettner S; Amini N; Pawlik TM
    J Surg Oncol; 2016 Sep; 114(3):361-7. PubMed ID: 27264476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.
    O Connor JM; Sanchez Loria F; Ardiles V; Grondona J; Sanchez P; Andriani O; Fauda M; Brancato F; Huertas E; Alvarez F; de Santibañes E
    Future Oncol; 2019 Sep; 15(27):3149-3157. PubMed ID: 31426677
    [No Abstract]   [Full Text] [Related]  

  • 20. Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?
    Rhaiem R; Duramé A; Primavesi F; Dorcaratto D; Syn N; Rodríguez ÁH; Dupré A; Piardi T; Fernández GB; Villaverde AP; Rodríguez Sanjuán JC; Santiago RF; Fernández-Moreno MC; Ferret G; Ben SL; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E; Kianmanesh R; Di Martino M
    Surgery; 2024 Jul; 176(1):124-133. PubMed ID: 38519408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.